Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TAS4464 |
Synonyms | |
Therapy Description |
TAS4464 inhibits NEDD8 activating enzyme (NAE), therefore inhibits tumor cell growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAS4464 | TAS4464 inhibits NEDD8 activating enzyme (NAE), therefore inhibits tumor cell growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176, PMID: 31583781, PMID: 31092565). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | clear cell sarcoma | not applicable | TAS4464 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TAS4464 inhibited growth and induced apoptosis in clear cell carcinoma cell lines in culture, resulted in tumor suppression in cell line xenograft models (Cancer Res 2016;76(14 Suppl):Abstract nr 3777). | detail... |
Unknown unknown | multiple myeloma | not applicable | TAS4464 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TAS4464 inhibited growth and induced apoptosis in multiple myeloma cell lines in culture, resulted in tumor suppression in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 1730). | detail... |
Unknown unknown | hematologic cancer | not applicable | TAS4464 | Preclinical - Cell culture | Actionable | In a preclinical study, TAS4464 demonstrated cytotoxicity in a number of hematologic cancer cell lines in culture (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176). | detail... |
Unknown unknown | acute lymphoblastic leukemia | not applicable | TAS4464 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TAS4464 resulted in complete tumor regression in cell line xenograft models of acute lymphocytic leukemia (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176). | detail... |
Unknown unknown | rhabdomyosarcoma | not applicable | TAS4464 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TAS4464 inhibited growth and induced apoptosis in rhabdomyosarcoma cell lines in culture, resulted in tumor suppression in cell line xenograft models (Cancer Res 2016;76(14 Suppl):Abstract nr 3777). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02978235 | Phase Ib/II | TAS4464 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma | Terminated | USA | 0 |